Neva Sgr presents results and launches two new funds

19 September 2024
Innovation Center, Innovation, Focus On, Finance

At the OGR in Turin, an event took place to discuss the results and present the new Neva II and Neva II Italia funds, dedicated to investing in companies committed to providing business solutions to global problems

On September 18, Neva Sgr, the venture capital firm of the Intesa Sanpaolo Group, fully owned by Intesa Sanpaolo Innovation Center, celebrated its fourth year of activity and launched the new Neva II and Neva II Italia funds. These funds will have a final investment capacity of 500 million euros, doubling the 250 million euros of the Neva First funds.
For the occasion, Neva Sgr brought together a large audience of venture capitalists, corporations, institutional investors, experts, entrepreneurs, and startup founders from all over Italy and many other countries, with the United States leading the way.
In the opening remarks, the President of Intesa Sanpaolo, Gian Maria Gros-Pietro, and the Chief Sustainability Officer of Intesa Sanpaolo and President of Intesa Sanpaolo Innovation Center, Paola Angeletti, highlighted the significant role Neva Sgr plays in Intesa Sanpaolo Group's sustainability strategies. Luca Remmert, President of Neva Sgr, also spoke about how one of Neva Sgr's objectives is to invest in companies that seek solutions to major global problems of the present and future.

evento Neva sgr alle OGR evento Neva sgr alle OGR

Encouraging Results and Future Prospects

Since August 2020, despite the challenges caused by the pandemic, Neva Sgr has exceeded its goals ahead of schedule. It has invested around 170 million euros in over 40 highly innovative and rapidly growing companies through its first three funds—Neva First for global investments, Neva First Italia dedicated to national companies, and Fondo Sei for the development of innovative ecosystems in Italy.
Mario Costantini, CEO and General Manager of Neva Sgr, presented the funds' ROIs and announced the early closure of the investment portfolio composition period for the Neva First fund, along with the first capital distribution to subscribers. This success was made possible by the enhanced value from exiting Cyberint's capital after its recent acquisition by the global cybersecurity operator Check Point.

Following the institutional speeches, the first panel discussion, moderated by Massimo Della Ragione, Professor of Practice in Investment Banking at Bocconi University and SDA Bocconi School of Management, featured founders and managers representing the diversified portfolio composition of Neva Sgr’s funds:
Guido Meardi, co-founder and CEO of V-Nova (innovative software for video and image compression technologies);
Guy Moskowitz, co-founder and CEO of Coro (Artificial Intelligence for Cybersecurity);
Luca Rossettini, co-founder and CEO of D-Orbit (space logistics and orbital transportation services);
Paolo Cavallini, Chief of Staff at Energy Dome (long-duration CO2 batteries);
Matteo Vanotti, co-founder and CEO of xFarm (digital management for agricultural companies).

For the new funds, Neva Sgr has set ambitious targets, supported by its strong track record, the gradual expansion of its international network, and the growing interest in Italy in venture capital as an investment tool for qualified operators and private clients.
Neva II aims to raise approximately 400 million euros to invest in the world's most innovative emerging companies, while Neva II Italia plans to raise 100 million euros to support Italian companies. Both funds will focus on companies operating in sectors of critical importance to the future of the planet: life sciences, energy transition, digital transformation, next-generation manufacturing, and aerospace.
Neva Sgr dedicated the second panel discussion of the event to life sciences, hosting representatives of two world-class leaders in cutting-edge medical research, both already part of Neva First's portfolio: Matthew Porteus, co-founder and CEO of Kamal Therapeutics (biotechnology for human genome editing), and Maria Grazia Roncarolo, co-founder, President, and Head of Research and Development at Tr1X (biotechnology for the treatment of autoimmune and inflammatory diseases).